

**09:20-10:00 – Session 1: Translational Research A**

**Chairpersons: A. Kotsakis, H. Timotheadou**

**09:20-09:35: A. Koumarianou**

**S6-05.** Gain-of-function kinase library screen identifies FGFR1 amplification as a mechanism of resistance to antiestrogens and CDK4/6 inhibitors in ER+ breast cancer

**S2-03.** Highly recurrent transcriptional remodeling events in advanced endocrine resistant ER-positive breast cancers

**09:35-09:50: F. Fostira**

**S5-04.** Prediction of occult invasive disease in ductal carcinoma in situ using deep learning features.

**GS4-06.** Cancer risks and response to targeted therapy associated with *BRCA2* variants of uncertain significance

**09:50-10:00: Q & A.**

**10:00-10:50 – Session 2: Translational Research B**

**Chairpersons: D. Pectasidis, Ch. Papadimitriou**

**10:00-10:15: G. Kallergi**

**S6-03.** Circulating tumor cells (CTCs) five years after diagnosis are prognostic for late recurrence in operable stage II-III breast cancer.

**S3-07.** Genome-wide copy number analysis of chemotherapy-resistant metastatic triple-negative breast cancer from cell-free DNA

**10:15-10:30: S. Kokkali**

**S1-03.** The comparative clinical utility of Ki67 at baseline and after 2 weeks of pre-operative aromatase inhibitor (AI) in predicting long-term outcome in early breast cancer - the POETIC\* trial (CRUK/07/015)

**GS3-08.** Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL.

**10:30-10:45: M. Rovithi**

**GS3-02.** Invasive disease-free survival and gene expression signatures in CALGB (Alliance) 40601, a randomized phase III neoadjuvant trial of dual HER2-targeting with lapatinib added to chemotherapy plus trastuzumab

**S6-04.** The EndoPredict score predicts residual cancer burden after neoadjuvant chemotherapy and after neoendocrine therapy in HR+/HER2- breast cancer patients from ABCSG 34.

**10:45-10:50: Q & A.**

**10:50-11:10: Coffee break**

**11:10-12:15 – Session 3: Local Therapy**

**Chairpersons: V. Venizelos, M. Kontos, G. Kyrgias**

**11:10-11:25: K. Anastasakou**

**S5-01.** Appropriate margins for breast conserving surgery in patients with early stage breast cancer: A meta-analysis

**S5-02.** Axillary dissection vs. no axillary dissection in patients with cT1-T2cN0M0 breast cancer and only micrometastases in the sentinel node(s): Ten-year results of the IBCSG 23-01 trial

**11:25-11:40: G. Metaxas**

**Best of posters: Surgery**

**11:40-12:00: G. Fillipou**

**GS5-08.** A validation of DCIS biological risk profile in a randomized study for radiation therapy with 20 year follow-up (SweDCIS)

**Best of posters: Radiotherapy**

**12:00-12:15: Discussion: S. Lanitis**

**12:15-13:35: Session 4 – Advanced Disease**

**Chairpersons: A. Alexopoulos, L. Vamvakas, S. Kakolyris**

**12:15-12:30: M. Nikolaidi**

**S2-05.** First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial

**S5-06.** A U.S. Food and Drug Administration pooled analysis of outcomes of older women with hormone-receptor positive metastatic breast cancer treated with a CDK4/6 inhibitor as initial endocrine based therapy

**12:30-12:45: M. Nikolaou**

**GS6-02.** The benefit of abemaciclib in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies

**S4-07.** Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor-positive breast cancer

**12:45-13:00: E. Kontopodis**

**S2-06.** Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: Results from the PANACEA (IBCSG 45-13/KEYNOTE-014) study

**S3-06.** Long-term follow-up of CALGB 40502/NCCTG N063H (Alliance): A randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-Paclitaxel (NP) or ixabepilone (IX) +/- bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer (MBC)

**13:00-13:15: G. Lypas**

**GS1-07.** Sacituzumab Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate, as ≥3rd-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer (mTNBC): efficacy results

**GS6-07.** EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced germline BRCA-mutation breast cancer.

**13:15-13:30: V. Barbounis PARP inhibitors: the new old.**

**13:30-13:35: Q & A.**

**13:35-14:00: Session 5 - Greek studies and best of posters**

**Chairpersons: A. Ardavanis, I. Drositis**

**Presenter: K. Tsapakidis**

**14:00-14:50: Session 6 – Survivorship Issues**

**Chairpersons: A. Psyrri, S. Kosmidi**

**14:00-14:15: A. Poultsidi**

**S4-04.** Randomized blinded sham- and waitlist-controlled trial of acupuncture for joint symptoms related to aromatase inhibitors in women with early stage breast cancer (S1200)

**S5-03.** Risk of arm morbidity after local therapy in young breast cancer survivors

**14:15-14:30: M. Skondra**

**S4-01.** Pooled analysis of five randomized trials investigating temporary ovarian suppression with gonadotropin-releasing hormone analogs during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients

**S5-07.** Weight change in postmenopausal women and breast cancer risk in the Women's Health Initiative Observational study

**14:30-14:45: Discussant: Z. Saridaki: diet and weight change issues for breast cancer survivors**

**14:45-14:50 Q & A.**

***14:50–15:30: Lunch break***

**15:30-16:40: Session 7 – Adjuvant Chemotherapy**

**Chairpersons: P. Kosmidis, K. Papazisis, C. Kourousis**

**15:30-15:45: N. Tsoukalas**

**S3-03.** A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT - Randomised EuropeAn Celecoxib Trial)

**S3-05.** Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based paclitaxel followed by anthracycline-cyclophosphamide for patients with early breast cancer - GBG69

**15:45-16:00: E. Ntouvelis**

**S3-04.** A randomized phase III study of adjuvant trastuzumab for duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer (the SOLD study).

**S1-06.** Extended adjuvant bisphosphonate treatment over five years in early breast cancer does not improve disease-free and overall survival compared to two years of treatment: Phase III data from the SUCCESS A study

**16:00-16:15: Y. Markou**

**S1-02.** NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC).

**S1-01.** Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and breast cancer mortality: an EBCTCG meta-analysis of 21,000 women in 16 randomised trials.

**16:15-16:30: Discussion: D. Tryphonopoulos: Dose-dense chemotherapy: does one size fit all?**

**16:30-16:40 Q & A.**

**16:40-17:40: Session 8 – Hormonal Therapy**

**Chairpersons: I. Boukovinas, A. Koutras**

**16:40-16:55: S. Karageorgopoulou**

**S3-01.** A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of Anastrozole after initial 5 years of adjuvant endocrine therapy - results from 3,484 postmenopausal women in the ABCSG-16 trial

**S6-01.** Integration of clinical variables for the prediction of late distant recurrence in patients with oestrogen receptor positive breast cancer treated with 5 years of endocrine therapy.

**16:55-17:10: E. Lalla**

**S4-02.** Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials

**S4-03.** Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Update of the SOFT trial

**17:10-17:30: E. Razis: tailoring hormonal therapy for pre-menopausal women.**

**17:30-17:40 Q & A.**

**17:40-18:10: Session 9 – Changes in clinical practice after SABCS 2017**

**Chairpersons: N. Androulakis, I. Athanasiadis**

**C. Christodoulou**

**18:15 Adjourn**